|
C2ORF3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63602464908763E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.25397478459399E-12 |
| Normal-vs-Stage2 |
1.01770000004997E-06 |
| Normal-vs-Stage3 |
3.09419156963031E-13 |
| Normal-vs-Stage4 |
2.12252437847837E-12 |
| Stage1-vs-Stage2 |
5.159200E-01 |
| Stage1-vs-Stage3 |
9.966100E-02 |
| Stage1-vs-Stage4 |
4.157600E-02 |
| Stage2-vs-Stage3 |
9.212300E-02 |
| Stage2-vs-Stage4 |
3.044000E-02 |
| Stage3-vs-Stage4 |
4.705600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-15 |
| Normal-vs-AfricanAmerican |
9.920400E-03 |
| Normal-vs-Asian |
2.90369950306513E-11 |
| Caucasian-vs-AfricanAmerican |
6.577600E-03 |
| Caucasian-vs-Asian |
9.837600E-01 |
| AfricanAmerican-vs-Asian |
2.704500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.92490048742411E-10 |
| Normal-vs-Female |
1.63014046705712E-12 |
| Male-vs-Female |
4.018800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.80320252857791E-11 |
| Normal-vs-Age(41-60Yrs) |
4.44089209850063E-15 |
| Normal-vs-Age(61-80Yrs) |
1.7614000258348E-09 |
| Normal-vs-Age(81-100Yrs) |
1.619260E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.234190E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.761400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.596200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.936500E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.511600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.717000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.3083999999971E-05 |
| Classical-VS-Follicular |
1.700210E-03 |
| Classical-VS-Other |
9.750200E-01 |
| Classical-VS-Normal |
1.63080660087189E-12 |
| Tall-VS-Follicular |
1.76900000203872E-08 |
| Tall-VS-Other |
2.142600E-01 |
| Tall-VS-Normal |
3.33066907387547E-16 |
| Follicular-VS-Other |
3.313400E-01 |
| Follicular-VS-Normal |
1.965650E-04 |
| Other-VS-Normal |
3.482500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.5026003491746E-10 |
| Normal-vs-N1 |
2.70661271173367E-12 |
| N0-vs-N1 |
2.906000E-02 |
|
|
